At a glance
ClinicalIndex Comparison RecordPhase 1Unknown· 20 target
Drug / intervention
Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injectionbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Study to Evaluate Safety and Efficacy of C-TIL052A Cell Therapy (Autologous Tumor Infiltrating Lymphocytes Injection Combined With IL-2) in Subjects With Persistent, Recurrent and/or Metastatic Cervical Cancer
In Brief
A Phase 1 clinical trial evaluating Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injection for Cervical Cancer. Targeting 20 participants across 2 sites.
Detailed Summary
A study that aimed to assess the safety and anti-tumor activity of C-TIL052A cell therapy in subjects with persistent, recurrent and/or metastatic cervical cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCervical Cancer
CountriesChina
CollaboratorsShanghai AbelZeta Ltd.
Timeline
Phase 1UnknownOverdue
2023202420252026
Enrollment StartJul 2022
First PostedJul 2022
Primary CompletionJul 2025
TodayJul 2026
First PostedJul 27, 2022
Enrollment StartJul 1, 2022
Primary CompletionJul 1, 2025
TodayJul 1, 2026
Enrollment to primary: 3 yearsPosted 3.9 years ago
Interventions
Autologous Tumor Infiltrating Lymphocytes (C-TIL052A) Injectionbiological
C-TIL052A injection followed by injection of IL-2